Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Abstract Background Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need is mainly due to the heterogeneity underlying both...

Full description

Bibliographic Details
Main Authors: Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch, Gabriella Honeth
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Breast Cancer Research
Subjects:
Metastatic breast cancer
Endocrine treatment resistance
Cell cycle inhibitors
Fulvestrant
Cyclin E2
Online Access:https://doi.org/10.1186/s13058-021-01402-1

Internet

https://doi.org/10.1186/s13058-021-01402-1

Similar Items